- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03895684
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
October 14, 2021 updated by: Salarius Pharmaceuticals, LLC
Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Phase 1, open-label, non-randomized dose finding study of SP-2577 given as oral tablets in patients with advanced solid tumors in 28-day cycles.
The study design is based on a Simon's 4B design without intrapatient dose escalation.
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- HonorHealth
-
-
California
-
Santa Monica, California, United States, 90403
- Sarcoma Oncology Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 12 years and weight ≥ 40 kg.
- Diagnosis of advanced or recurrent, histologically or cytologically confirmed, solid malignancy that is either metastatic or unresectable. At time of enrollment, subjects must have progressed on, be intolerant of, refuse, or ineligible for, all available standard of care therapies.
- Subjects must demonstrate measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, with the exception of castration-resistant prostate cancer (CRPC) who should have progression based on the PCWG 3.0 criteria
- Karnofsky ≥70% for over ≥16 years old and Lansky ≥70% for under 16 years old, equivalent to Eastern Cooperative Oncology Group (ECOG) performance status grade 0 or 1
- Willingness to provide tumor biopsies of assessible lesions on and off treatment (Dose expansion cohort only). Optional for patients <18 years of age.
- Able to swallow and retain orally administered medication.
- Patients must have normal organ and marrow function
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Subjects with Ewing Sarcoma. See NCT03600649, Protocol Number: SALA-002-EW16.
- Subjects with primary central nervous system tumors
- Patients who have not recovered to grade 1 or baseline from adverse events related to prior therapy excluding lymphopenia, alopecia, peripheral neuropathy and ototoxicity, which are excluded if ≥ CTCAE grade 3 (Version 5.0).
- Patients who are receiving any other investigational agents.
- Prior therapy with LSD1 targeted agents including monoamine oxidases for cancer therapy.
- Prior systemic anti-cancer treatment (chemotherapy, biologic therapy [ie. small molecular inhibitors, monoclonal antibodies]) within 21 days prior to Cycle 1 Day 1.
- Prior therapy with immunotherapy such as a checkpoint inhibitor, cellular therapy or vaccine therapy within 28 days prior to Cycle 1 Day 1. Patients must have recovered from any immune-related adverse events to grade 1 or baseline and require ≤ 10 mg of prednisone equivalents daily. Patients with immune-related hypothyroidism and/or hypoadrenalism may enroll while on thyroid or hydrocortisone replacement therapy, respectively.
- Prior small port palliative radiotherapy within 14 days or 42 days from definitive local control radiation (any dose greater than 50Gy).
- Anti-androgen therapies for prostate cancer, such as bicalutamide, within 4 weeks prior to enrollment. Second-line hormone therapies such as enzalutamide, abiraterone, or orteronel within 2 weeks prior to enrolment. Subjects with prostate cancer should remain on luteinizing hormone releasing hormone (LHRH) agonists or antagonists. Subjects with prostate cancer may also remain on low-dose prednisone or prednisolone up to 10 mg/day
- Prior therapy with long acting myeloid growth factor within 14 days or 7 days from a short acting myeloid growth factor.
- Participation in a prior investigational study within 30 days prior to Cycle 1 Day 1.
- Patients with progressive or symptomatic brain metastases. Patients with brain metastases may be included in this trial as long as the brain metastases have received definitive treatment and are stable (i.e., no evidence of progression). The brain metastases must be stable for a minimum of 6 weeks.
- Patients must have discontinued anti-seizure medications and steroids, except for physiologic steroid dosing (≤10 mg/day of prednisone equivalents).
- Patients currently receiving any of the following substances and cannot be discontinued 14 days prior to Cycle 1 Day 1: Moderate or strong inhibitors or inducers of major CYP isoenzymes, including grapefruit, grapefruit hybrids, pomelos, star-fruit, and Seville oranges; Moderate or strong inhibitors or inducers of major drug transporters; Substrates of CYP3A4/5 with a narrow therapeutic index
- Uncontrolled concurrent illness including, but not limited to: ongoing or active infection; transfusion dependent thrombocytopenia or anemia; psychiatric illness/social situations that would limit compliance with study requirements
- Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following: symptomatic congestive heart failure; Left Ventricular Ejection Fraction (LVEF) ≤ 50%; unstable angina pectoris or cardiac arrhythmia; baseline QTcF (Fridericia) ≥ 450 milliseconds; Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome
- Any major surgery within 21 days prior to Cycle 1 Day 1.
- Pregnant and breastfeeding women
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
- HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with SP-2577. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sp-2577
Twice-daily administration of oral SP-2577
|
Dose escalation and dose expansion of SP-2577.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of SP-2577
Time Frame: From screening through at least 30 days after end of treatment, up to approximately 24 months
|
Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0
|
From screening through at least 30 days after end of treatment, up to approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the maximum tolerated dose of SP-2577
Time Frame: DLTs within the first cycle of therapy (up to 28 days)
|
Defined as the dose level immediately below the dose level at which ≥ 2 patients from a cohort of 3 to 6 patients experience a dose-limiting toxicity (DLT).
|
DLTs within the first cycle of therapy (up to 28 days)
|
Characterization of pharmacokinetics of SP-2577 (area under the concentration time profile)
Time Frame: At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
SP-2577 under fasted and fed conditions
|
At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
Characterization of pharmacokinetics of SP-2577 (time to maximum plasma concentration)
Time Frame: At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
SP-2577 under fasted and fed conditions
|
At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
Characterization of pharmacokinetics of SP-2577 (maximum plasma concentration)
Time Frame: At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
SP-2577 under fasted and fed conditions
|
At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
Characterization of pharmacokinetics of SP-2577 (half-life)
Time Frame: At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
SP-2577 under fasted and fed conditions
|
At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
Characterization of pharmacokinetics of SP-2577 (clearance rate)
Time Frame: At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
SP-2577 under fasted and fed conditions
|
At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
Characterization of pharmacokinetics of SP-2577 (volume of distribution)
Time Frame: At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
SP-2577 under fasted and fed conditions
|
At protocol defined time points on cycle 1 (each cycle is 28 days), day 1 and 2 and cycle 2, day 1 and 2.
|
Efficacy parameter: overall response rate of SP-2577
Time Frame: From start of treatment through at least 30 days after end of treatment, up to approximately 24 months
|
Assessed by radiographic imaging with response and progression evaluated by RECIST 1.1 guidelines
|
From start of treatment through at least 30 days after end of treatment, up to approximately 24 months
|
Efficacy parameter: duration of response of SP-2577
Time Frame: From start of treatment through at least 30 days after end of treatment, up to approximately 24 months
|
Assessed by radiographic imaging with response and progression evaluated by RECIST 1.1 guidelines
|
From start of treatment through at least 30 days after end of treatment, up to approximately 24 months
|
Efficacy parameter: progression-free survival of SP-2577
Time Frame: From start of treatment through at least 30 days after end of treatment, up to approximately 24 months
|
Assessed by radiographic imaging with response and progression evaluated by RECIST 1.1 guidelines
|
From start of treatment through at least 30 days after end of treatment, up to approximately 24 months
|
Changes in serum hemoglobin F concentrations
Time Frame: At protocol defined time points from start of treatment through end of treatment, up to approximately 24 months
|
Determine changes serum hemoglobin F concentrations correlated with SP-2577 treatment and clinical and radiographic markers of disease burden (either response or resistance/progression).
|
At protocol defined time points from start of treatment through end of treatment, up to approximately 24 months
|
Changes in the molecular signatures of the tumor
Time Frame: At protocol defined time points from start of treatment through end of treatment, up to approximately 24 months
|
Assessed in dose expansion only by RNA-seq testing of tumor biopsy samples to determine changes in gene expression patterns by SP-2577 treatment to elucidate biological changes induced in the tumor by LSD1 inhibition.
|
At protocol defined time points from start of treatment through end of treatment, up to approximately 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 25, 2019
Primary Completion (ACTUAL)
April 13, 2021
Study Completion (ACTUAL)
April 13, 2021
Study Registration Dates
First Submitted
February 14, 2019
First Submitted That Met QC Criteria
March 28, 2019
First Posted (ACTUAL)
March 29, 2019
Study Record Updates
Last Update Posted (ACTUAL)
October 18, 2021
Last Update Submitted That Met QC Criteria
October 14, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SALA-003-AC19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
Clinical Trials on SP-2577 Seclidemstat
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Chronic Myelomonocytic Leukemia-0United States
-
HonorHealth Research InstituteMerck Sharp & Dohme LLC; Salarius Pharmaceuticals, LLCWithdrawnOvarian Endometrioid Adenocarcinoma | Endometrial Cancer | SCCOHT | Ovarian Clear Cell TumorUnited States
-
Salarius Pharmaceuticals, LLCNational Pediatric Cancer FoundationActive, not recruitingEwing Sarcoma | Myxoid Liposarcoma | Fibromyxoid Tumor | Sarcoma,Soft Tissue | Desmoplastic Small Round Cell Tumor | Angiomatoid Fibrous Histiocytoma | Extraskeletal Myxoid Chondrosarcoma | Clear Cell Sarcoma | Primary Pulmonary Myxoid Sarcoma | Myoepithelial Tumor | Sclerosing Epithelioid FibrosarcomaUnited States
-
Fotona d.o.o.UnknownStress Urinary IncontinenceCanada
-
L&C BioPROMeDisRecruitingHerniation, DiscKorea, Republic of
-
Ruijin HospitalRecruiting
-
JhpiegoBarcelona Institute for Global HealthCompletedMalaria in PregnancyCongo, The Democratic Republic of the, Madagascar, Mozambique, Nigeria
-
Salarius Pharmaceuticals, LLCNot yet recruitingLymphoma, Non-Hodgkin's, Adult
-
Semnur Pharmaceuticals, Inc.Worldwide Clinical Trials; Scilex Pharmaceuticals, Inc.CompletedLumbosacral Radicular PainUnited States
-
Morris Innovative IncorporatedDeborah Heart and Lung CenterUnknownVascular DiseasesUnited States